Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may unlock long COVID secrets

NCT ID NCT05758480

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This completed study took blood samples from 62 people with Long COVID and compared them to healthy controls. Researchers looked for specific immune and metabolic patterns that might explain why symptoms persist. The goal is to better understand Long COVID, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify biological markers that define Long COVID, potentially leading to better diagnosis and future treatments.
What could go wrong
This is a small, observational study that only looks for patterns in blood samples. It does not test any treatment, so it may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

May 2023

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

A/ Inclusion Criteria: * For all patients: * Age \> 18 years * Symptomatic COVID-19 diagnosed after 01JAN2021, confirmed by RT-PCR or Antigen test * Last SARS-CoV-2 infection diagnosed more than 12 weeks before inclusion * Patient covered by the French health insurance * Signature of the informed consent * For patient with Long COVID : * At least one of the following symptoms during the week preceding inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia) * Absence of Return to Usual Health after SARS-CoV-2 infection (patient declaration) * Absence of alternative diagnosis for the symptoms * For COVID-19 recovered patient (Control) : * None of the following symptoms in the 3 week before inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia) * Return to Usual Health after SARS-CoV-2 infection (patient declaration) B/ Exclusion Criteria: * History of severe COVID-19 (Hospitalization) * Symptoms caused by sequelae of SARS-CoV-2 infection (in particular, persistence of lung parenchymal abnormalities : pulmonary fibrosis, persistent alveolitis on CT-Scan) * Significant Depression or anxiety symptoms, as assessed by a \> 10 score on the A or D items of the Hospital anxiety and depression scale (HAD) * Presence of one of the following diseases: * Inborn errors of metabolism * estimated Glomerular filtration rate \< 30 ml/min (MDRD) * Autoimmune disease * Immunosuppressive treatment or immune deficiency * Symptomatic heart failure * Respiratory failure (COPD stage ≥ 3 or oxygen therapy) * Solid cancer or active blood disease * Severe malnutrition (albumin \< 30 g/L or weight loss ≥10% in 6 months) * Obesity with BMI ≥ 35 kg/m² * Diabetes not controlled by diet alone * Pregnant, breastfeeding or parturient women * Deprivation of liberty by judicial or administrative decision * Mandatory Psychiatric Care * Protected by decision of law * Unable to express consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Angers University Hospital

    Angers, 49933, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.